Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Waverley Pharma

Waverley Pharma?uq=w9if130k
PUBLIC STATUS
WAVE STOCK SYMBOL
1 INVESTMENTS
$0.20 SHARE PRICE (As of Thursday Closing)
Description

Developer of small molecule therapeutics intended to commercialize pharmaceutical drugs for the treatment of cancer. The company's small molecule therapeutics is dedicated to the development and commercialization of safe, effective and affordable cancer therapeutics, enabling patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
TSX
Primary Office
  • 4-1250 Waverley Street
  • Winnipeg, Manitoba R3T 6C6
  • Canada
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Waverley Pharma’s full profile, request a free trial.

Waverley Pharma Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.20 - $0.47 $10.7M $0.20 -$0.03 1K 54M

Waverley Pharma Financials Summary

In Thousands,
USD
TTM
31-Mar-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 816 1,074
Revenue 0 0
EBITDA (2,157) (1,809) (1)
Net Income (2,150) (1,816) (1)
Total Assets 4,808 5,295 0
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Waverley Pharma Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Waverley Pharma‘s full profile, request access.

Request full access to PitchBook

Waverley Pharma Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000 25-Oct-2017 000000000000000000 Holding Companies
To view this company’s complete investment and acquisition history, request access »

Waverley Pharma Executive Team (1)

Name Title Board
Seat
Contact
Info
George Thomas Ph.D President & Chief Executive Officer